DAYTONA BEACH, FL–(Marketwired – May 23, 2014) – Quture International, Inc. (OTCQB: QUTR) (“Q”) the proven and experienced clinical performance and outcome analytics and solutions company in American healthcare, now with global capability, today announced successful completion of its Go to Market Plan for its QualOptima Versions 1 and 2 technology for installations and sales to existing and new customers. Q’s extensive development of the QualOptima Connectivity & Analytics System for customer segments and value propositions, including embedded intellectual property, has resulted in potential sale of the full transformational software system for healthcare enterprise management in Version 2.0 at intended reference sites. The Marketing Plan for Version 2.0 focuses on the Clinical Trial at the University of Miami/Jackson Memorial Hospital. Initial marketing, sales and installations in process are for the previously announced Professional Practice Evaluation Application in Version 1 of QualOptima. Marketing and commercial sales are focused on five (5) versions of QualOptima, for software as a service (SaaS) or bundled with consulting through Q’s subsidiary QualVal Solutions, LLC, to penetrate the estimated $2.5 billion market in the United States with intentions to expand globally through Q’s subsidiary Quture Euro, LLC.
In collaboration with InterSystems Corporation (www.InterSystems.com), Q is expanding its application of InterSystems’ tools Cache, Ensemble, DeepSee and iKnow and information technology (IT) staffing with addition of a Chief Software Architect and staff for planned installations, support and training of all versions of QualOptima. The QualOptima Versions 1 is the Practice Evaluation Application with Version 1.3 integrating performance measurement with peer review and previously announced Version 1.5 proctoring for evaluation of current clinical competence. The array of InterSystems strategic technology platform is leveraged adding Version 1.2 Qtriggers to machine read narrative text in medical records for clinical quality improvement and patient safety opportunities for improvement and optimizing revenue while reducing healthcare costs. Version 1.2 will implement iKnow technology with another licensed technology of Q for this natural language processing (NLP) data analytics platform to even further differentiate Q and its QualOptima product in the healthcare market.
Commercial sales and installations of these QualOptima versions have required expanding Q management, staff and infrastructure. Q’s market analysis includes compliance requirements, clinical quality and patient safety, revenue enhancement, value-driven care and value-based purchasing, and enterprise management through outcomes analytics. The Go to Market Plan focuses on the initial market of Q to healthcare providers and payers to achieve optimal clinical, financial and operational outcomes.
“Q’s confidence in its intellectual property and technology to become the market leader from our first mover position in clinical outcomes analytics and solutions has increased exponentially as the needs of healthcare customers evolve,” said Landon Feazell, Chairman and CEO of Quture. “Q’s Go to Market Plan envisions all potential customer segments, ranging from providers like hospitals, physician groups, HMOs, and Accountable Care Organizations, to payers like health insurers and exchanges and other insurers, especially medical malpractice companies, to pharmaceutical companies and medical device manufacturers, to consultants like healthcare law firms, financial and accounting firms, regulators and government entities.”
The QualOptima Analytics & Connectivity System is transformative technology to enhance clinical performance to achieve optimal patient outcomes. As the free enterprise solution to improving health and healthcare while reducing costs, Q is positioned through its disruptive technology to become the foremost global provider of value-based clinical intelligence and knowledge solutions.
“Our long-term strategy is to market to additional customer segments to provide the platform and clinical knowledge solutions to empower interchange of information between patients, providers and payers for the changing medical model,” said Feazell. “With the power of our technology platform to exchange information through mobile applications, Q is extremely confident in our marketing and technology development strategies for Q’s short and long-term future.”
About Quture International, Inc.
Quture International (OTCQB: QUTR) is the proven and experienced clinical performance and outcome analytics and solutions company in American healthcare. Q’s first-to-market clinical intelligence software is the complete solution for healthcare providers, payers, employers, and insurance companies seeking to achieve optimal clinical, financial and operational outcomes. Q’s QualOptima Connectivity & Analytics System empowers value-driven, patient-centered, personalized care focused on real-time and predictive patient management and patient safety, with optimal quality demonstrated by outcomes correlated with resource use, revenue and cost. As an Application Partner of InterSystems Corporation, Q’s software operates on their HealthShare strategic technology platform to capture, integrate, aggregate, and analyze data transformed to knowledge in Q’s innovative second-generation database. InterSystems (www.intersystems.com) has customers in over 100 countries with 80% of top hospitals in America currently utilizing its technology. Q’s core competence and value proposition lies in its embedded evidence-based metrics, clinical content and analytic algorithms developed from over 35 years of measuring performance in hundreds of hospitals, physician organizations and HMO’s.
As the free enterprise solution to improving health and healthcare while reducing costs, Q is positioned through its disruptive technology to become the foremost global provider of value-based clinical intelligence and knowledge solutions. Q is a Nevada corporation based in Daytona Beach, Florida, and trades on the OTC exchange under the symbol ‘QUTR.’
Forward Looking Statements: This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.